Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312)

According to the results of a randomized phase II trial among patients with bone metastases from lung cancer, the time to first skeletal-related event (SRE) did not differ between those who received 4 mg zoledronic acid every 4 weeks compared with every 8 weeks (HR 1.18; 95% CI: 0.48, 2.9; P = 0.715). After 12 months of treatment, the SRE rate was 17.6% (95% CI: 8.4, 30.9%) and 23.3% (95% CI: 11.8, 38.6%), respectively.